Boston Scientific Retains Right To Absorb Reva Medical Under Equity Deal
This article was originally published in The Gray Sheet
Executive Summary
Reva Medical's unique slide-and-lock bioabsorbable stent design has attracted equity investment from Boston Scientific, which previously expressed doubts about the viability of the biodegradable stent concept
You may also be interested in...
Reva Medical IPO Will Fund ReZolve Bioresorbable Stent Study In Early 2011
Reva Medical's ReZolve bioresorbable drug-eluting stent is set to enter a pilot clinical study in the first quarter of 2011, funded by a planned $63 million initial public stock offering, the company says
Reva Medical IPO Will Fund ReZolve Bioresorbable Stent Study In Early 2011
Reva Medical's ReZolve bioresorbable drug-eluting stent is set to enter a pilot clinical study in the first quarter of 2011, funded by a planned $63 million initial public stock offering, the company says
Boston Scientific Plans 2008 Post-Warning Letter Interventional Launches
Boston Scientific plans to launch four new interventional cardiology products in 2008 after resolving a two-and-a-half-year-old company-wide FDA warning letter